Genitourinary long-term outcomes for childhood cancer survivors.
The treatment of pediatric malignancies represents one of the success stories of modern medicine. As survival has increased, the focus is now on minimizing harmful effects of treatment. There continue to be late toxicities and secondary malignancies of the genitourinary (GU) system for childhood cancer survivors related to the specific therapeutic exposures. A systematic approach is important for prevention and treatment of these adverse late GU effects.
Shnorhavorian
Margarett
M
margarett.shnorhavorian@seattlechildrens.org
Friedman
Debra L
DL
Koyle
Martin A
MA
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D002648:Child; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D006304:Health Status; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology*; D011788:Quality of Life; D011879:Radiotherapy Dosage; D017741:Survivors; D001749:Urinary Bladder Neoplasms; D014551:Urinary Tract / Q000187:drug effects*; D014565:Urogenital Neoplasms / Q000139:chemically induced / Q000453:epidemiology*
D000970:Antineoplastic Agents